期刊
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
卷 16, 期 2, 页码 77-84出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/13651501.2012.667114
关键词
Anxiety disorders; guidelines; panic disorder; generalized anxiety disorder; social anxiety disorder; pharmacological treatment
类别
资金
- AstraZeneca
- Bristol-Myers-Squibb
- Glaxo-SmithKline
- Jazz
- Merck
- Lilly
- Lundbeck
- Ono Pharma
- Otsuka
- Pfizer
- Servier
- Teva
- Abbott BMS
- Janssen
- Nastech
- Neuropharm
- Wyeth
- Bristol-Myers Squibb
- CSC
- Eli Lilly
- Janssen Pharmaceutica
- MSD
- Novartis
- Organon
- Pierre Fabre
- Schwabe
- Sepracor
- Janssen Cilag
Objective. Anxiety disorders are frequently under-diagnosed conditions in primary care, although they can be managed effectively by general practitioners. Methods. This paper is a short and practical summary of the World Federation of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder (OCD) and posttraumatic stress disorder (PTSD) for the treatment in primary care. The recommendations were developed by a task force of 30 international experts in the field and are based on randomized controlled studies. Results. First-line pharmacological treatments for these disorders are selective serotonin reuptake inhibitors (for all disorders), serotonin-norepinephrine reuptake inhibitors (for some) and pregabalin (for generalized anxiety disorder only). A combination of medication and cognitive behavior/exposure therapy was shown to be a clinically desired treatment strategy. Conclusions. This short version of an evidence-based guideline may improve treatment of anxiety disorders, OCD, and PTSD in primary care.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据